Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

• Status: Withdrawn
• Trial end date: 1969-12-31

Summary

The goal of this clinical research study is to find the highest tolerable dose of seliciclib that can be given in combination with liposomal doxorubicin to patients with metastatic breast cancer.

• Phase: Phase 1

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Institutes of Health (NIH)
• Treatments: Doxorubicin; Liposomal doxorubicin; Roscovitine